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A B S T R A C TObjectives: In the Russian Federation, cardiovascular disease (CVD) is
the primary cause of death and premature death; however, to date,
there have been no systematic cost-of-illness studies to assess the
economic impact of CVD.Methods: The economic burden of CVD was
estimated from statistic data on morbidity, mortality, and health care
resource use. Health care costs were estimated on the basis of
expenditure on primary, outpatient, emergency, and inpatient care,
as well as medications. Non–health care costs included economic
losses due to morbidity and premature death in the working age.
Results: CVD was estimated to cost Russia RUR 836.1 billion (€24,517.8
million) in 2006 and RUR 1076 billion (€24,400.4 million) in 2009. Of the
total costs of CVD, 14.5% in 2006 and 21.3% in 2009 were due to health
care, with 85.5% and 78.7%, respectively, due to non–health care costs.
Conclusions: CVD is a leading public health problem. We ﬁrstsee front matter Copyright & 2013, International S
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, Petroverigski Lane, 10, 101990, Moscow, Russia.assessed the economic burden of CVD in Russia. Our results can be
used for planning investments in prevention programs and measures
for improving care for patients with CVD. Regular monitoring of the
economic burden of CVD in the future at the federal, regional, and
municipal levels will allow assessment of the dynamics of economic
burden, as well as the effectiveness of investments in the economy in
primary and secondary prevention. Because data are relatively
unavailable, there are important limitations to this study, which
highlight the need for more accurate CVD-speciﬁc information.
Keywords: cardiovascular disease, coronary heart disease, cerebro-
vascular diseases, cost-of-illness study, economic burden, Russia.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In the Russian Federation, cardiovascular disease (CVD) is the
primary cause of death and premature death [1]. There has been,
however, no systematic cost-of-illness study to assess its eco-
nomic impact. The World Bank calculated health care expendi-
tures in two regions of Russia and extrapolated these data to the
entire country [2]. These regions, however, were not representa-
tive of the entire country because the calculations included only
health care costs. Another attempt to calculate the economic
burden of CVDs in Russia was made by the World Health
Organization. It calculated the economic burden for 2005 and
predicted a prognosis of burden for 2015 and 2030 of the most
prevalent noncommunicable diseases from a macroeconomic
perspective based on death rate [3].
The objectives of this study were to estimate the economic
costs of CVD in Russia, including health care costs and produc-
tivity loss, and to estimate the proportion of total CVD cost
attributable to coronary heart disease (CHD) and cerebrovascular
diseases as was estimated in the study of Leal et al. [4] in the
European Union (EU).Methods
Methodological Background
Cost-of-illness analyses involved the identiﬁcation, measure-
ment, and valuing of resources related to CVD in Russia in the
period 2006 to 2009. The calculation included health care costs
and costs outside the health care sector (productivity losses
associated with premature death or morbidity and disability
pensions). All expenditures were measured for the period 2006
to 2009 in the prices of the appropriate year. Additional ﬁle 1
includes the sources of information used for calculations.
The national currency rubles was converted to euros (€) by
using a weighted exchange rate for the period 2006 to 2009.
Epidemiological and health care utilization data were acquired
from the Ministry of Health of the Russian Federation and the
market research company COMCON from the published litera-
ture. Analysis was based on the International Statistical Classiﬁca-
tion of Diseases, 10th Revision (ICD-10) categories: CVD (ICD-10
category I00–I99), hypertensive diseases (ICD-10 category I10–
I15), CHD (ICD-10 category I20–I25), and cerebrovascular diseaseociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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calculations are listed in the Additional information ﬁle.
Health Care Expenditure
The following categories of CVD health care services were included
in the calculations: primary and outpatient care, accident and
emergency (A&E) care, hospital inpatient care, cardiosurgery and
percutaneous coronary interventions (PCIs), and medications. Car-
diosurgery and PCI expenditures were calculated separately from
hospital inpatient care because they are ﬁnanced through different
sources in Russia. Hospital inpatient care is paid by the health
insurance system, while cardiosurgery and PCIs are paid by direct
payment from the federal budget in the framework of the federal
program on high technology and costly medical care or by the
patient. Other types of activities related to the CVD were not
included because of the difﬁculties in locating information. Data
for A&E care and hospital inpatient care were received from the
Ministry of Health of the Russian Federation; data on primary and
outpatient care were obtained from several information sources;
and data on medications were received from annual pharmacoepi-
demiology surveys through the COMCON company and other
literature data.
Health Service Utilization
Primary and outpatient care
Primary care activities consisted of CVD-related visits to general
practitioners (GPs), as well as GP visits to patients’ homes. There is a
speciﬁc statistical form for all medical organizations that includes
data on the number of patients who visited this organization for
outpatient care during the year according to the ICD-10 categories.
This statistical form is centrally received in the Ministry of Health
and processed as a single form for the entire country. We received a
single form for the entire country for 2006 to 2009. The number of
visits for each outpatient was calculated on the basis of these
statistical forms and data from previous studies examining the
mean number of visits of patients with CVD during the year.
Hospital inpatient care
Inpatient care was estimated on the basis of the number of CVD-
related days in the hospital. There is also a speciﬁc statistical
form for all inpatient medical organizations that includes data on
the number of hospitalizations and number of hospital days in
this organization during the year according to the ICD-10 catego-
ries. This statistical form is also centrally received in the Ministry
of Health and processed as a single form for the entire country.
We received the statistical single form for inpatient care in Russia
for 2006 to 2009 and selected data on ICD-10 categories of interest.
A&E care
A&E care consisted of all CVD-related hospital emergency visits.
A 2009 special statistical form for all inpatient medical organ-
izations included information regarding the number of hospital
emergency visits according to the ICD-10 categories. We selected
data on ICD-10 categories in 2009 and extrapolated these values
for 2006 to 2008.
Cardiosurgery and PCI
The main cardiosurgery institution in Russia, the Bakoulev Center
for Cardiovascular Surgery, centrally collects information from all
medical organizations involved in such interventions in Russia and
annually publishes a statistical yearbook. We selected data regard-
ing the number of PCI, coronary artery bypass grafting, and some
other cardiosurgeries performed in Russia in 2006 to 2009.Health care unit costs
Unit costs of an inpatient day, outpatient visit, and emergency visit
were obtained from the Ministry of Health. The ofﬁcial Web site
annually publishes information on the mean costs of inpatient days,
outpatient visits, and emergency visits in different specialties and
total expenditures in the framework of the program of the govern-
mental guarantees of the medical care.
The costs of cardiosurgery and PCI paid directly by the federal
budget are published annually on the Web site of the Ministry of
Health in the description of the Federal Program on High
Technology and Costly Medical Care.
Expenditure on medication
There are no national sources of information regarding national
expenditures on medications in Russia. We used data from several
pharmacoepidemiology surveys made in Russia in 2006 to 2009 and
extrapolated these data for the entire country. The main source was
the databases of annual surveys conducted by the COMCON
company; other studies were used to identify patients with CVD
regularly taking medication for long periods as well as some other
data. Costs of medications were calculated on the basis of mean
prices during the studding years, including value added tax (VAT).
Non–Health Service Costs
Non–health service costs included productivity losses associated
with premature death and morbidity and disability pensions.
Because little information was found on informal care costs and
out-of-pocket expenses across the country, these costs were not
included in the calculations.
Estimation of productivity costs due to premature death during
working age
Productivity costs due to premature death during working age
included the gross domestic product (GDP) per employed person
related to CVD attributable to mortality.
The productivity loss from CVD-mortality was estimated by
calculating the following:1. number of CVD-related deaths during working age (retirement
age is 60 years for men and 55 years for women);2. number of remaining work years at the time of death (to
estimate the likely GDP that an individual who died would
have otherwise produced);3. annual GDP per employed person; and
4. economic activity and unemployment rates.
Future GDP was not indexed in the main analysis, as the usual
discount rate of 3% to 3.5% is not reasonable for Russia. The
inﬂation rate was 9% in 2006, 11.9% in 2007, 13.3% in 2008, and
8.8% in 2009. The effects of indexation on productivity costs using
rates of 10% and 15% were studied through sensitivity analysis.
Estimation of productivity costs due to cardiovascular morbidity
Morbidity costs were deﬁned as those associated with CVD-
attributable absence from work, estimated by multiplying the
number of certiﬁed days off work due to CVD by GDP produced in
one working day.
The number of CVD-related working days lost was obtained
from a special statistical form for all medical organizations that
included data on the number of disability days during the year
according to the ICD-10 categories. This statistical form is also
centrally received at the Ministry of Health and processed as a
single form for the entire country. We received a single form for
working days lost in Russia for 2006 to 2009 and selected data on
ICD-10 categories related to CVD.
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We examined the effects of 20% changes in health care costs.
Because medication costs were estimated by using subjective
assumptions, the effect of 50% changes in these categories was
tested. We also assessed the effects of indexation on productivity
costs by using rates of 10% and 15%.Results
Table 1 shows the average unit costs used for calculations and
those aggregated from different sources.
Health Care Costs
CVD accounted for more than 69.6 million hospital bed days in
Russia in 2006 and 68.0 million in 2009. The number of hospital-
izations did not change, but the mean duration of hospital stay
decreased each year (from 15.0 to 14.1 days). The number of
hospital bed days for CHD was 27.1 million in 2006 and 26.3 million
in 2009, and for cerebrovascular diseases it was 17.6 and 17.2
million, respectively. CVD represented 479.2 hospital bed days per
1000 persons in 2009 (Table 2), 185.2 days for CHD, and 121.2 days
for cerebrovascular diseases. This parameter is higher than the
total for the EU [4] but comparable to some European countries.
The number of GP and outpatient visits was 1603.2 per 1000
persons in 2009, with CHD representing 300.9 visits for 1000
persons and cerebrovascular diseases representing 286.6 (Table 2).
CVD cost Russian health care systems approximately RUR 121
billion or €3558.5 million in 2006 and (Table 3) RUR 229.5 billion or
€5204.4 million in 2009. The major component of CVD-related
health care expenditure was inpatient care, which accounted for
RUR 52.7 billion (€1545.1 million) in 2006 and RUR 109 million
(€2470.8 million) in 2009, representing 43.4% and 47.5% of total
health care costs, respectively. CVD-related medication expendi-
ture was also a large cost, representing 27% in 2006 (RUR 32.6
billion) of total costs and 21% in 2007 (RUR 47.6 billion) of health
care costs. The third largest component of CVD-related health care
expenditure was outpatient care, which represented 20.2% of the
total health care costs in 2006 and 21.7% of the total health care
costs in 2009. The other two cost components (emergency care and
cardiosurgery) accounted for 9.5% in 2006 and 10.0% in 2009 of
costs, with A&E representing the smallest component. The struc-
ture of the CVD costs in Russia was similar to that of the EU [4],
where inpatient care and pharmaceutical expenditure were major
components of CVD-related health care expenditure.
Non–Health Care Costs
Mortality losses were relatively high in Russia because of high CVD
death rates in the general population and in the working age
population. The number of CVD deaths per 1000 persons was several
times higher than in Europe [4]. There is a prominent difference inTable 1 – Average unit costs in Russia in 2006–2009.
2006 200
Ruble Euro Ruble
GDP per employed person
Annual 389,021 11,408.2 467,463
Daily 1,195 35.0 1,445
Health care unit cost
GP and outpatient visit 115 3.4 149
A&E visit 686 20.1 888
Inpatient day 754 22.1 947
A&E, accident and emergency; GDP, gross domestic product; GP, generalthe number of deaths in working-age men and women. The death
rate of working-age men (younger than 60 years) was 3.2 in Russia in
2009, while for working-age women it was 0.7. This explains the
signiﬁcant difference in working year losses between men and
women (22.1 and 3.4 for 1000 persons in 2009). In the EU, working
year losses in men were also higher than in women [4], but to a
lesser degree than in Russia. CHD accounted for approximately half
of CVD mortality losses, while values for cerebrovascular diseases
were much lower, particularly regarding working-year losses.
CVD accounted for 2.1 million working years lost in 2006 and
1.7 million in 2009 owing to deaths during working ages. GDP
losses due to mortality in working ages were estimated to cost
approximately RUR 630 billion (€18,483.3 million) in 2006 and RUR
117.1 billion (€16,509.6) in 2009, respectively, after adjusting for
working status (Table 3).
There were 70.1 million working days lost in 2006 and 67.3
million in 2009 because of CVD morbidity. This represented a cost
of RUR 83.8 billion (€2458.4 billion) in 2006 and RUR 117.4 billion
(€2662.5 billion) in 2009 after adjusting for working status
(Table 3). The costs of disability pensions were rather small,
€17.7 million in 2006 and €23.9 million in 2009.
Total Costs of CVD
Overall, CVD was estimated to cost the Russian economy RUR
836.1 billion (€24,517.8 million) in 2006 and RUR 1076 billion
(€24,400.4 million) in 2009 (Table 3). Of the total costs of CVD,
14.5% in 2006 and 21.3% in 2009 were due to health care, whereas
non–health care costs were 85.5% and 78.7%, respectively. The
structure of costs is completely different from the EU data, where
the health care cost was the most signiﬁcant [4].
Share of GDP (CVD)
The total costs of CVD were equal to 3.1% of the GDP of the
Russian Federation in 2006 and 2.8% in 2009, respectively
(Table 4).
Costs of CHD and Cerebrovascular Diseases
The total costs of CHD were RUR 339.7 billion (€9962.2 million) in
2006 (Table 4) and RUR 406.6 billion (€9220.4 million) in 2009. Health
care costs were RUR 58.6 billion (€1719.0 million) and RUR 103.9
billion (€2355.2 million) in 2009. The share of health care costs
relative to total costs increased from 17.3% in 2006 to 25.5% in 2009.
The total costs of cerebrovascular diseases were much
lower than those of CHD. Total care costs were RUR 139.2 billion
(€4083.3 million) in 2006 and RUR 184.5 billion (€4183.9 million) in
2009. Health care cerebrovascular costs were RUR 18.8 billion
(€551.9 million) in 2006 (Table 4) and RUR 38.6 billion (€874.1
million) in 2009. The share of health care costs compared with
total costs increased from 13.5% in 2006 to 20.9% in 2009.7 2008 2009
Euro Ruble Euro Ruble Euro
13,668.5 584,338 16,053.2 562,500 12,755.1
42.3 1,837 50.5 1,745 39.6
4.4 181 5.0 219 5.0
26.0 1,110 30.5 1,387 31.5
27.7 1,232 33.8 1,602 36.3
practitioner.
Table 2 – Resource units per 1000 population in the Russian Federation in 2009.
CVD CHD Cerebrovascular diseases
Mortality losses
Deaths
All 8.0 4.1 2.6
Men 7.8 4.2 2.2
Women 8.2 4.0 3.0
Working years lost
All 11.1 4.5 1.9
Men 22.1 9.1 3.5
Women 3.4 0.9 0.8
Morbidity losses
Working days lost 474.2 80.1 73.3
Health care unit
GP and outpatient visits 1603.2 300.9 286.6
Hospital emergency visits 47.9 5.1 10.6
Inpatient days 479.2 185.2 121.2
CHD, coronary heart disease; CVD, cardiovascular disease; GP, general practitioner.
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Varying total health care costs upwards and downwards by 20%
produced a variation of 1% in the baseline of total CVD-related
costs in the period 2006 to 2009. Our results did not vary
signiﬁcantly when the assumptions used to derive medication
cost estimates were varied by 50%, resulting in changes of 1% in
total costs.
Future earning losses at a 10% discount rate were associated
with a reduction of 8% in costs, while a 15% discount rate was
associated with a reduction of 11% in costs.Discussion
This is the ﬁrst study to estimate the full burden of CVD,
including health care and non–health care costs in Russia. We
estimated that the total burden of CVD varied between €24.4
and €32.3 billion in the period 2006 to 2009. In a recent European
study, the estimated cost of CVD was €169 billion [4]. Because
the population of EU is several times higher than that of Russia,
the amounts were comparable. We found, however, that theTable 3 – Cost of CVD in Russia in 2006–2009.
2006 200
RUR
million
€
million
RUR
million
Inpatient care 52,687.9 1,545.1 65,791.5
Primary and outpatient care 24,469.5 717.6 32,385.6
A&E care 4,032.4 118.3 5,614.5
Cardiosurgery and PCI 7,517.5 220.5 9,451.6
Medications 32,637.0 957.1 35,249.0
Total health care costs 121,344.3 3,558.5 148,492.3
GDP losses due to mortality in
working age
630,280.4 18,483.3 687,087.1
GDP losses due to morbidity 83,830.7 2,458.4 104,067.2
Disability pensions 602.2 17.7 666.7
Total non–health care costs 714,713.3 20,959.3 791,821.0
Total costs 836,057.6 24,517.8 940,313.3
A&E, accident and emergency; CVD, cardiovascular disease; GDP, gross
rubles.structures of the total costs were completely different in Russia
and the EU. A European study found that health care expendi-
ture accounted for 61% of costs, but in our study the share of
health care expenditures was only 14.5% of total costs in 2006
and 21.3% in 2009. If our study included the cost of informal
care, health care costs would be even lower. Non–health care
costs (mainly due to premature death during working age)
account for 80% of total CVD costs in Russia.
Direct costs associated with CVD in the EU included costs for
hospital admissions (57%), costs for drug therapy (27%), and costs
for ambulatory care and A&E (16%) [4]. In general, the structure of
direct costs in our study was similar.
In our study, the share of health care costs for CVD relative to
total costs was 13.5% to 20.9%. In the study of 27 EU countries, it
was shown that total costs from stroke were 68.5% due to direct
costs and 31.5% due to indirect costs [5]. In the United States, the
economic burden of stroke includes 67% of direct health care
costs and 33% of losses in the economy due to premature
mortality and disability days [6]. Thus, in Russia, the structure
of the economic burden of CVD is different from that due to the
predominance of indirect costs.7 2008 2009
€
million
RUR
million
€
million
RUR
million
€
million
1,923.7 85,283.7 2,343.0 108,960.9 2,470.8
946.9 40,262.8 1,106.1 49,833.0 1,130.0
164.2 7,410.2 203.6 9,425.8 213.7
276.4 11,701.9 321.5 13,714.5 311.0
1,030.7 40,124.4 1,102.3 47,578.7 1,078.9
4,341.9 184,783.0 5,076.5 229,513.0 5,204.4
20,090.3 860,872.9 23,650.4 728,075.2 16,509.6
3,042.9 127,864.4 3,512.8 117,416.1 2,662.5
19.5 833.8 22.9 1,054.1 23.9
23,152.7 989,571.0 27,186.0 846,545.4 19,196.0
27,494.5 1,174,354.0 32,262.5 1,076,058.3 24,400.4
domestic product; PCI, percutaneous coronary intervention; RUR,
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 9 9 – 2 0 4 203Several studies demonstrated that health care costs for
various CVDs differ signiﬁcantly depending on the country, the
length of hospitalization, and other factors [7–9].
CHD was the most costly CVD (37.8% of total CVD costs).
According to estimates of economic burden in the United States,
CHD was also the most expensive disorder [10]. In a European study,
CHD accounted for 27% of total costs [4]. A UK study showed that
CHD and stroke costs were similar (29% and 27% of total CVD costs,
respectively) [11]. In some studies, it was shown that myocardial
infarction typically accounts for the largest share of CHD costs
owing to long hospitalization and costly interventions [12,13].
Studies examining the economic burden of diseases enable
comparisons between the burdens of different diseases, allowing
decision makers to prioritize limited research funds to areas with
the highest burden [14]. Furthermore, if such studies are per-
formed at regular intervals, the impact of health policy decisions
can be measured. In Russia, these studies can be used to monitor
governmental programs involved in chronic disease prevention.
The results of calculations performed in this study can be
used to plan investments in prevention programs and improve
care to patients with CVD. Regular monitoring of the economic
burden of CVD in the future at the federal, regional, and
municipal levels will allow the assessment of the dynamics of
economic burden, as well as the effectiveness of investments in
the economy in primary and secondary prevention.
The next step of such studies is to estimate the economic cost
of risk factors of chronic disease. This will provide support for
prioritizing resources for prevention and public health [15].
To be in a better position to inform policy decisions aimed at
reducing the burden of disease, improved information regarding
epidemiology and accurate information regarding resource use
and unit costs is imperative. In Russia, there is lack of recent
reliable epidemiology data as well as gaps in the ofﬁcial statistics
on resource use.
Our results are likely underestimated. Some categories of
costs, such as costs of informal care, were not included because
of data limitations.
Despite these acknowledged and important data limitations,
this is the ﬁrst study to quantify the burden of CVD in Russia.Acknowledgments
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